ALPMF (Astellas Pharma) FFO


ALPMF Astellas Pharma Inc ALPMF
73 GF Score
Price $14.20
GF Value $14.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma FFO?

FFO (Funds from operations) only applies to REITs.

ALPMF
73GF Score
Astellas Pharma Inc ALPMF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of $14.20 is trading 0.1% above its estimated GF Value™ of $14.18. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • FFO:
  • GF Value™: $14.18 vs. price of $14.20 (0.1% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score

Get the complete analysis for ALPMF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.20
Price
$14.18
GF Value